SQI Diagnostics

NEW YORK (GenomeWeb) – Toronto-based SQI Diagnostics continues to see its CustomPlex diagnostic tools and services business generate revenue as interest in its technology from pharmaceutical industry partners increases.

Trilochan Sahoo is CombiMatrix's new director of cytogenetics. Sahoo joins the Irvine, Calif.-based molecular testing services firm from Quest Diagnostics Nichols Institute, where he was senior director of cytogenetics. He also served as laboratory director at Signature Genomics.

NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI Diagnostics today announced it raised gross proceeds of C$4.2 million (US$3.8 million) in a public offering.

NEW YORK (GenomeWeb News) – Health Canada has issued a license to SQI Diagnostics allowing the company to market its multiplexed Ig_plex Celiac DGP Panel, the Toronto-based firm said today.

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

Andrew Morris has joined SQI Diagnostics' board of directors.

NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI Diagnostics today reported zero revenues for its fiscal second quarter.

NEW YORK (GenomeWeb News) – SQI today said it has raised almost C$3.85 million (US$3.81 million) in a non-brokered private placement of its stock.

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced a non-brokered private placement intended to raise C$3.76 million (US$3.72 million) in gross proceeds.

SQI Diagnosticsand Algorithme Pharma have developed a microarray-based assay targeted at the immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.